These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 24982505)

  • 41. MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
    Novosad O; Skrypets T; Pastushenko Y; Titorenko I; Martynchyk A; Skachkova O; Inomistova M; Gorbach A; Khranovska N; Kryachok I
    Klin Onkol; 2018; 31(2):130-136. PubMed ID: 29708356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease.
    Satoh T; Smith A; Sarde A; Lu HC; Mian S; Trouillet C; Mufti G; Emile JF; Fraternali F; Donadieu J; Geissmann F
    PLoS One; 2012; 7(4):e33891. PubMed ID: 22506009
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ddPCR Analysis Reveals BRAF V600E Mutations Are Infrequent in Isolated Pituitary Langerhans Cell Histiocytosis Patients.
    Nellan A; Bodlak A; Mirsky DM; Mulcahy Levy J; Garrington TP; Foreman NK; Gilani A; Hayashi M
    J Neuropathol Exp Neurol; 2020 Dec; 79(12):1313-1319. PubMed ID: 32930721
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Co-existence of BRAF V600E-mutated malignant melanoma and BRAF V600E-mutated Langerhans cell histiocytosis: A case report.
    Goto K; Yoshikawa S; Kiyohara Y; Kukita Y; Miura K; Oishi T
    J Cutan Pathol; 2022 Apr; 49(4):393-398. PubMed ID: 34792818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recurrent BRAF mutations in Langerhans cell histiocytosis.
    Badalian-Very G; Vergilio JA; Degar BA; MacConaill LE; Brandner B; Calicchio ML; Kuo FC; Ligon AH; Stevenson KE; Kehoe SM; Garraway LA; Hahn WC; Meyerson M; Fleming MD; Rollins BJ
    Blood; 2010 Sep; 116(11):1919-23. PubMed ID: 20519626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.
    Zarnegar S; Durham BH; Khattar P; Shukla NN; Benayed R; Lacouture ME; Lavi E; Lyden DC; Diamond EL; Dunkel IJ; Abdel-Wahab O
    Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748614
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases.
    Roden AC; Hu X; Kip S; Parrilla Castellar ER; Rumilla KM; Vrana JA; Vassallo R; Ryu JH; Yi ES
    Am J Surg Pathol; 2014 Apr; 38(4):548-51. PubMed ID: 24625419
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of BRAF V600E mutation in radiological Langerhans cell histiocytosis-associated neurodegenerative disease using droplet digital PCR analysis.
    Shimizu S; Sakamoto K; Kudo K; Morimoto A; Shioda Y
    Int J Hematol; 2023 Jul; 118(1):119-124. PubMed ID: 37010809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
    Berres ML; Lim KP; Peters T; Price J; Takizawa H; Salmon H; Idoyaga J; Ruzo A; Lupo PJ; Hicks MJ; Shih A; Simko SJ; Abhyankar H; Chakraborty R; Leboeuf M; Beltrão M; Lira SA; Heym KM; Bigley V; Collin M; Manz MG; McClain K; Merad M; Allen CE
    J Exp Med; 2014 Apr; 211(4):669-83. PubMed ID: 24638167
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.
    Kemps PG; Zondag TCE; Arnardóttir HB; Solleveld-Westerink N; Borst J; Steenwijk EC; van Egmond D; Swennenhuis JF; Stelloo E; Trambusti I; Verdijk RM; van Noesel CJM; Cleven AHG; Scheijde-Vermeulen MA; Koudijs MJ; Krsková L; Hawkins C; Egeler RM; Brok J; von Bahr Greenwood T; Svojgr K; Beishuizen A; van Laar JAM; Pötschger U; Hutter C; Sieni E; Minkov M; Abla O; van Wezel T; van den Bos C; van Halteren AGS
    Blood Adv; 2023 Feb; 7(4):664-679. PubMed ID: 36083130
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [BRAF-V600E mutation and its clinical significance in children with Langerhans cell histiocytosis].
    Tang X; Guo X; Sun LY; Ai Y; Yang X; Sun JJ; Wu JR; Gao J
    Zhongguo Dang Dai Er Ke Za Zhi; 2018 Apr; 20(4):290-294. PubMed ID: 29658453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.
    Johnson WT; Patel P; Hernandez A; Grandinetti LM; Huen AC; Marks S; Ho J; Monaco SE; Jaffe R; Picarsic J
    J Cutan Pathol; 2016 Mar; 43(3):270-5. PubMed ID: 26454140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan.
    Sasaki Y; Guo Y; Arakawa F; Miyoshi H; Yoshida N; Koga Y; Nakashima K; Kurita D; Niino D; Seto M; Ohshima K
    Hematol Oncol; 2017 Sep; 35(3):329-334. PubMed ID: 27041734
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.
    Messinger YH; Bostrom BC; Olson DR; Gossai NP; Miller LH; Richards MK
    Pediatr Blood Cancer; 2020 Dec; 67(12):e28712. PubMed ID: 32991018
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of BRAF-Inhibitor Therapy in BRAF
    Hazim AZ; Ruan GJ; Ravindran A; Abeykoon JP; Scheckel C; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Bennani NN; Rech KL; Young JR; Shah MV; Goyal G; Go RS
    Oncologist; 2020 Dec; 25(12):1001-1004. PubMed ID: 32985015
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
    Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
    Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
    Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
    Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BRAF-V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first-line therapy.
    Wang CJ; Zhu T; Zhao CZ; Cui H; Wang D; Zhao ZJ; Huang XT; Li HL; Liu FF; Zhang R; Li ZG; Cui L
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31099. PubMed ID: 38845144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Apparent Lack of
    Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
    Front Immunol; 2019; 10():3045. PubMed ID: 31998317
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis.
    Murakami I; Matsushita M; Iwasaki T; Kuwamoto S; Kato M; Nagata K; Horie Y; Hayashi K; Imamura T; Morimoto A; Imashuku S; Gogusev J; Jaubert F; Takata K; Oka T; Yoshino T
    Cell Commun Signal; 2015 Feb; 13():13. PubMed ID: 25889448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.